CardioFocus, Inc. has filed for key patents for its technology designed to treat atrial fibrillation, which is a type of abnormal heartbeat.
Earlier this year, the Marlborough medical device manufacturer filed the patent for its HeartLight System pulse field ablation technology, which is designed to maintain contact with a vein important to maintaining a regular heartbeat.
The company expects the technology to have its first human use in 2023, according to a Tuesday press release from the company.
“We believe HeartLight enables best-in-class patient results by providing an ablation platform that will facilitate the creation of precise lesions and thereby predictable, efficient cases,” CardioFocus CEO & President Burke Barrett said in the press release. “We are thrilled by the patient outcomes and the excitement we have seen with our HeartLight X3 laser-based therapy.”
